Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654918 | 0.93 | MAPT (0.54) | TSHRALDH1A1MAPTKMT2ACES1 | |
| SCHEMBL28812563 | 0.91 | TSHR (0.46) | TSHRALDH1A1MAPTKMT2ACES1 | |
| SCHEMBL11743168 | 0.91 | MAPT (0.57) | TSHRMAPTKMT2ACES1CES2 | |
| SCHEMBL9345659 | 0.91 | MAPT (0.57) | TSHRMAPTKMT2ACES1CES2 | |
| SCHEMBL17629047 | 0.91 | MAPT (0.57) | TSHRMAPTKMT2ACES1CES2 | |
| SCHEMBL11745435 | 0.91 | MAPT (0.57) | TSHRMAPTKMT2ACES1CES2 | |
| SCHEMBL10734584 | 0.91 | MAPT (0.57) | TSHRMAPTKMT2ACES1CES2 | |
| SCHEMBL11740658 | 0.91 | MAPT (0.57) | TSHRMAPTKMT2ACES1CES2 | |
| SCHEMBL11749087 | 0.91 | MAPT (0.57) | TSHRMAPTKMT2ACES1CES2 | |
| SCHEMBL515402 | 0.91 | TSHR (0.56) | TSHRALDH1A1MAPTKMT2ACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56120681-A | — | — | None | — | — | JP | disclosed |
| US-20230096312-A1 | RESIST COMPOSITION AND METHOD FOR USING RESIST COMPOSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-9714271-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160207961-A1 | Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3 | ACHILLE LIFE SCIENCES LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9200038-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CICLOFILIN PHARMACEUTICALS CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| CN-102369173-B | Method for producing high-purity terminal olefin compound | KURARAY CO | 2014-09-10 | — | — | CN | disclosed |
| US-20140142033-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ISOTECHNIKA PHARMA INC. (CA) | 2014-05-22 | — | — | US | disclosed |
| EP-2415740-B1 | METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND | KURARAY CO (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8609886-B2 | Method for producing high purity terminal olefin compound | KURARAY CO., LTD. (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20130190223-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | ISOTECHNIKA PHARMA INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| EP-1694803-B1 | HYDROPHOBIC MODIFIED DIQUATERNARY MONOMERS AND POLYMERS AS THICKENING AGENTS OF ACIDIC AQUEOUS COMPOSITIONS | RHODIA (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2415740-A1 | METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND | Kuraray Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029229-A1 | METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND | KURARAY CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| JP-S56120681-A | PREPARATION OF (Z)-8-NONEN-5-ONE DERIVATIVE | SAGAMI CHEM RES CENTER | 1981-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190223-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | CD40, FKBP1A, FKBP4 | TSHR 2593/4885ALDH1A1 2494/4885MAPT 4681/4885 |
| US-20160207961-A1 | Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3 | FKBP1A, CHP1, FKBP3 | TSHR 4502/4885ALDH1A1 3240/4885MAPT 3843/4885 |
| US-20140142033-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | FKBP1A, CHP1, FKBP3 | TSHR 4502/4885ALDH1A1 3240/4885MAPT 3843/4885 |
| US-20120029229-A1 | METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND | ADH1A, ADH1C, OSBP | TSHR 3218/4885ALDH1A1 233/4885MAPT 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.